Advertisement

What is the relevance of resistance of Helicobacter pylori to antimicrobial agents?

  • F. Mégraud

Abstract

The need to treat a Helicobacter pylori infection when associated with diseases such as peptic ulcer is now universally recognized.

Keywords

Triple Therapy Pylorus Eradication Minimal Inhibitory Concen Eradication Rate Pylorus Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davis DB. Chemotherapy. In: Davis DB, Dulbecco R, Eisen HN et al., editors. Microbiology, 4th edn. Philadelphia: Lippincott; 1990:201–8.Google Scholar
  2. 2.
    Veldhuyzen Van Zanten SJ, Goldie J, Holligsworth J et al. Secretion of intravenously administered antibiotics in gastric juice: implication for management of Helicobacter pylori. J Clin Pathol. 1992;45:225–7.CrossRefGoogle Scholar
  3. 3.
    Harrison JD, Jones JA, Morris DC. Azithromycin levels in plasma and gastric tissue, juice and mucus. Eur J Clin Microbiol Infect Dis. 1991;10:862–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Darmaillac V, Bouchard S, Lamouliatte H, Mégraud F. Macrolides and Helicobacter pylori — determination of MICs and effect of pH. Gastroenterology. 1995;108:A78.Google Scholar
  5. 5.
    Mégraud F, Malfertheiner P. Treatment of Helicobacter pylori infection: summary of a meeting at the fourth United European Gastroenterology Week. Helicobacter. 1996; 1:118–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Labenz J, Gyenes E, Rühl GH, Borsch G. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol. 1993;88:491–5.PubMedGoogle Scholar
  7. 7.
    Butzler JP, Mégraud F. Campylobacter and Helicobacter pylori. In: Zinner S, Young L, Acar J, editors. New macrolides, azalides and streptogramins in clinical practice. New York: Marcel Dekker; 1996 (In press).Google Scholar
  8. 8.
    Occhialini A, Urdaci M, Doucet-Populaire F, Lamouliatte H, Bébéar CM, Mégraud F. Helicobacter pylori resistance to macrolides — confirmation of point mutation and detection by PCR-RFLP. Gut. 1996 (In press).Google Scholar
  9. 9.
    Versalovic J, Shortridge D, Kibler K et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother. 1996;40:477–80.PubMedGoogle Scholar
  10. 10.
    Xia HX, Buckley M, Keane CT, O’Morain CA. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother. 1996; 37:473–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Mégraud F, Camou-Juncas C, Occhialini A, Birac C. Helicobacter pylori resistance levels to clarithromycin remain stable. Gastroenterology. 1996; 100: A192.Google Scholar
  12. 12.
    Camou C, Ancelle J, Lamouliatte H, Mégraud F. Evolution of the resistance of Helicobacter pylori to macrolides. ICMAS 96, Lisbon.Google Scholar
  13. 13.
    Cayla R, Zerbib F, Talbi P, Mégraud F, Lamouliatte H. Pre and post treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure. Gut. 1995;37(Suppl. 1):A55.Google Scholar
  14. 14.
    Shültze K, Hentschel E, Hirschl AM. Clarithromycin or amoxicillin plus high dose ranitidine in the treatment of Helicobacter pylori positive functional dyspepsia. Eur J Gastroenterol Hepatol. 1996;8:41–6.CrossRefGoogle Scholar
  15. 15.
    Wurzer H, Rodrigo L, Archambault A et al. Short course therapy with amoxicillin-clarithroymcin triple for 10 days (ACT 10) eradicates H. pylori and heals duodenal ulcer. Gut. 1996 (In press).Google Scholar
  16. 16.
    Glupczynski Y, Labbé M, Hansen W et al. Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J Clin Microbiol. 1991;29:2072–5.PubMedGoogle Scholar
  17. 17.
    Hirschl AM, Hirschl MM, Rotter ML. Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole. J Antimicrob Chemother. 1993;32:45.PubMedCrossRefGoogle Scholar
  18. 18.
    Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother. 1992;29:115–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Zwet AA, Thijs JC, de Graaf B. Explanation for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains. Antimicrobiol Agents Chemother. 1995;39:250–2.Google Scholar
  20. 20.
    Smith MA, Edwards DI. Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs. J Antimicrobiol Chemother. 1995;35:751–64.CrossRefGoogle Scholar
  21. 21.
    Burette A, Glupczynski Y, Deprez C et al. Omeprazole alone or in combination with clarithromycin for eradication of Helicobacter pylori, results of a randomized double-blind controlled study. Gastroenterology. 1993;104:49.Google Scholar
  22. 22.
    Noach LA, Bosma NB, Tytgat GNJ. Clarithromycin resistance and Helicobacter pylori infection. European United Gastroenterology Week, Barcelona 1993;A103.Google Scholar
  23. 23.
    Lian JX, Carrick J, Daskalopoulos G. Metronidazole resistance significantly affects eradication of Helicobacter pylori infection. Gastroenterology. 1993; 104:133.Google Scholar
  24. 24.
    Logan RPH, Gummett PA, Misiewicz JJ et al. One week eradication regimen for Helicobacter pylori. Lancet. 1991;338:1249–52.PubMedCrossRefGoogle Scholar
  25. 25.
    Bell GD, Powell K, Burridge SM et al. Experience with triple anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992;6:427–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Rautelin H, Kosunen TU, Seppala K. Eradicating Helicobacter pylori. Lancet. 1992;339:55.PubMedCrossRefGoogle Scholar
  27. 27.
    Moayyedi P, Sahay P, Tompkins DS, Axon ATR. Efficacy and optimum dose of omeprazole in a new 1-week triple regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol. 1996; 7:835–40.Google Scholar
  28. 28.
    Buckley M, Xia HX, Hyde D, O’Morain C. Cost effective, European approach to Helicobacter pylori eradication. Gut. 1995;37(Suppl. 2):A175.Google Scholar
  29. 29.
    Misiewicz JJ, Harris AW, Bardhan KD, Levis S, Langworthy H. One week low-dose triple therapy for eradication of H. pylori: a large multi centre randomised trial. Gastroenterology. 1996; 110: A198.Google Scholar

Copyright information

© Kluwer Academic Publishers and Axcan Pharma 1996

Authors and Affiliations

  • F. Mégraud

There are no affiliations available

Personalised recommendations